AbsEn.i
Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « chloroquine »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
chinese < chloroquine < choice  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 13.
Ident.Authors (with country if any)Title
000005 (2020) Tadeusz Płusa[Options for controlling new Corona virus infection - 2019-nCoV].
000042 (2020) Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000075 (2020) Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]Thoughts on COVID-19 and autoimmune diseases
000099 (2020) Carlo Perricone [Italie] ; Paola Triggianese [Italie] ; Elena Bartoloni [Italie] ; Giacomo Cafaro [Italie] ; Angelo F. Bonifacio [Italie] ; Roberto Bursi [Italie] ; Roberto Perricone [Italie] ; Roberto Gerli [Italie]The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
000187 (2020) Durga Prasanna Misra [Inde] ; Vikas Agarwal [Inde] ; Armen Yuri Gasparyan ; Olena Zimba [Ukraine]Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
000199 (2020) Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000223 (2020) Chih-Chia Lu [République populaire de Chine] ; Mei-Yu Chen [République populaire de Chine] ; Yuh-Lih ChangPotential therapeutic agents against COVID-19: What we know so far
000254 (2020) Yan Guo [République populaire de Chine] ; Hai Li [République populaire de Chine] ; Xueying Chen [République populaire de Chine] ; Huasheng Yang [République populaire de Chine] ; Hongyu Guan [République populaire de Chine] ; Xiaoying He [République populaire de Chine] ; Yuxin Chen [République populaire de Chine] ; Sunil Pokharel [République populaire de Chine] ; Haipeng Xiao [République populaire de Chine] ; Yanbing Li [République populaire de Chine]Novel Roles of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
000321 (2020) Biswaranjan Paital [Inde] ; Kabita Das [Inde] ; Sarat Kumar Parida [Inde]Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India
000447 (2020) Ming Zhao [République populaire de Chine]Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
000506 (2020) Awadhesh Kumar Singh [Inde] ; Akriti Singh [Inde] ; Altamash Shaikh [Inde] ; Ritu Singh [Inde] ; Anoop Misra [Inde]Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
000552 (2020) Tomasz J. Guzik [Royaume-Uni] ; Saidi A. Mohiddin [Royaume-Uni] ; Anthony Dimarco [Royaume-Uni] ; Vimal Patel [Royaume-Uni] ; Kostas Savvatis [Royaume-Uni] ; Federica M. Marelli-Berg [Royaume-Uni] ; Meena S. Madhur [États-Unis] ; Maciej Tomaszewski [Royaume-Uni] ; Pasquale Maffia [Royaume-Uni] ; Fulvio D'Acquisto [Royaume-Uni] ; Stuart A. Nicklin [Royaume-Uni] ; Ali J. Marian [États-Unis] ; Ryszard Nosalski [Royaume-Uni] ; Eleanor C. Murray [Royaume-Uni] ; Bartlomiej Guzik [Pologne] ; Colin Berry [Royaume-Uni] ; Rhian M. Touyz [Royaume-Uni] ; Reinhold Kreutz [Allemagne] ; Dao Wen Wang [République populaire de Chine] ; David Bhella [Royaume-Uni] ; Orlando Sagliocco [Italie] ; Filippo Crea [Italie] ; Emma C. Thomson [Royaume-Uni] ; Iain B. Mcinnes [Royaume-Uni]COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
000585 (2020) Zakir Khan [Pakistan] ; Yusuf Karata [Turquie] ; Hazir RahmanAnti COVID-19 Drugs: Need for More Clinical Evidence and Global Action

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "chloroquine" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "chloroquine" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    chloroquine
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021